<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112257">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01641900</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH092638</org_study_id>
    <nct_id>NCT01641900</nct_id>
  </id_info>
  <brief_title>Effects of Eszopiclone on Sleep and Memory in Schizophrenia</brief_title>
  <official_title>Sleep-dependent Memory Processing in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that the sleep medication, eszopiclone, can
      normalize brain activity during sleep and improve memory in patients with schizophrenia. The
      investigators will do this by comparing sleep and performance in participants taking
      eszopiclone to participants taking placebo. The investigators will study healthy subjects
      and patients with schizophrenia taking atypical antipsychotic medications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep spindles</measure>
    <time_frame>spindles will be averaged over the 2 study nights</time_frame>
    <description>Measurements of sleep spindle parameters based on polysomnographic recordings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor procedural memory performance</measure>
    <time_frame>On each of two study visits, that are separated by one week, participants will spend two consecutive nights in the hospital. Performance will be assesed the morning after the second night of each visit.</time_frame>
    <description>Performance on a finger tapping motor sequence task will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>eszopiclone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg. of eszopiclone for two consecutive nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule for two consecutive nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eszopiclone</intervention_name>
    <description>3 mg of eszopiclone for two consecutive nights</description>
    <arm_group_label>eszopiclone</arm_group_label>
    <other_name>Lunesta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule for two consecutive nights</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically stable outpatients with schizophrenia,

          -  proficient in English,

          -  able to give informed consent,

          -  maintained on a stable dose of atypical antipsychotic medications for at least 6
             weeks prior to enrollment.

          -  healthy Control participants matched as a group to the patients for age, sex, and
             parental socioeconomic status.

        Exclusion Criteria:

          -  Substance abuse or dependence within the past six months;

          -  other chronic medical conditions that affect sleep; (- pregnancy/breast feeding;

          -  hepatic impairment;

          -  treatment with inhibitors or inducers of CYP 3A4 or 2E1 enzymes (which metabolize
             eszopiclone);

          -  a history of head injury resulting in prolonged loss of consciousness or other
             neurological sequelae; (- mental retardation; (- a diagnosed sleep disorder other
             than insomnia,

          -  neurological disorder; sleep disorder, other than insomnia, identified in a clinical
             sleep evaluation.

        Patients on conventional agents, benzodiazepines, or other sleep agents will be excluded.
        Potential controls will be excluded for a personal history of mental illness, a family
        history of schizophrenia spectrum disorder or psychosis, and treatment with medications
        known to affect sleep or cognition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dara S Manoach, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Vuper, BS</last_name>
    <phone>617-726-1908</phone>
    <email>tcvuper@nmr.mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Vuper, BS</last_name>
      <phone>617-726-1908</phone>
      <email>tcvuper@nmr.mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Dara S Manoach, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 1, 2015</lastchanged_date>
  <firstreceived_date>January 25, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dara S. Manoach, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Psychology, Dept. of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>memory</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>eszopiclone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eszopiclone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
